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Calcium (Ca2þ ) and magnesium (Mg2þ ) ions are involved in
many vital physiological functions. In the human body, Ca2þ
and Mg2þ homeostatic systems rely on three components:
(i) tissues (re)absorbing or storing Ca2þ and Mg2þ , mainly
kidney, intestine, and bone; (ii) hormones that modulate the
transport and mobilization of these minerals; and (iii) sensors
controlling the transport of Ca2þ and Mg2þ in tissues. So far,
the Ca2þ -sensing receptor (CaSR) is the only known sensing
mechanism involved in the response to systemic and local
fluctuations in Ca2þ and Mg2þ concentrations. The tight
coupling of the Ca2þ and Mg2þ homeostasis is frequently
observed in humans and in animal models. Moreover, during
the past decade, the intense research on mineral disorders,
seen in the course of chronic kidney disease with secondary
hyperparathyroidism, has revealed the interplay between
Ca2þ and Mg2þ homeostasis. Altogether this evidence
points to the CaSR as an interesting target to study mutual
disturbances in Ca2þ and Mg2þ balance. Although many
homeostatic processes involving CaSR in the parathyroid
glands and kidneys have been elucidated, the current
knowledge of the inter-regulation of divalent handling by the
CaSR is still limited. Insight into the systemic and local
sensing of Ca2þ and Mg2þ by the CaSR, as well as the
identification of other receptors/sensors for these cations,
will unravel the mechanism controlling their coupled
regulation, and will lead to new treatment concepts for
mineral disorders.
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The cloning and characterization of the extracellular calcium
(Ca2þ )-sensing receptor (CaSR) from parathyroid glands,
kidney, and several other cell types have demonstrated that
Ca2þ ions can participate actively in their own regulation
through receptor-mediated interactions.1–3 In the parathy-
roid, CaSR controls peripheral Ca2þ homeostasis in the
kidney, bone, and intestine by modulating the secretion
of the parathyroid hormone (PTH) in response to low
circulating levels of ionized Ca2þ . In other tissues, local
CaSR activation triggers adaptive responses to microenviron-
mental variations in Ca2þ levels.
CaSR belongs to family C of the superfamily of G
protein–coupled receptors that also includes the receptors for
the main neurotransmitters glutamate and g-aminobutyric
acid. The CaSR consists of an extracellular domain of 612
amino acids, a 250 amino acid transmembrane domain of
seven transmembrane helices, and a 200 amino acid carboxy-
terminal C-tail.4 At the plasma membrane, CaSR resides as a
disulfide-linked dimer. The presence of two or more binding
sites for Ca2þ on each monomer results in a positive
cooperativity that allows the receptor to respond over a
narrow range of ligand concentrations, compared with other
members of the same family. Mg2þ , Sr2þ , La3þ , Gd3þ , and
highly positively charged organic compounds, such as
polyamines (e.g. spermine), aminoglycoside antibiotics (e.g.
neomycin), protamine, and polyarginine are also able to
activate the receptor, even in the absence of extracellular
Ca2þ . These polycationic agonists are termed type I agonists.
Type 2 agonists, in contrast, require the presence of Ca2þ to
activate CaSR and include L-amino acids and other organic
compounds that act as allosteric activators of the receptor
(the so-called calcimimetics).
Upon agonist binding, conformational changes in the
transmembrane domain and intracellular domains trigger a
number of intracellular signaling pathways. A characteristic
signature of CaSR activation is the mobilization of intracel-
lular Ca2þ via activation of phospholipase C. This leads to
modulation of the activity of many channels and receptors,
hormone secretion (e.g. PTH, calcitonin, growth hormone,
adrenocorticotropic hormone, gastrin, insulin), and regula-
tion of cellular activities such as proliferation, differentiation,
apoptosis, and gene expression.5,6 Initially investigated in
parathyroid glands and kidney, CaSR-mediated processes
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have been largely defined also in other tissues and are object
of intense research.7–10
The study of activating and inactivating CaSR mutations
in human disorders,11–13 the development of mouse models
for CaSR defects,14,15 and the identification of genetic poly-
morphisms in the CaSR gene16,17 have delineated a pivotal
role for the receptor in divalent mineral ion (Ca2þ and
Mg2þ ) homeostasis, phosphate (Pi) metabolism, and water
reabsorption. This review aims to summarize our current
knowledge about Ca2þ - and Mg2þ -sensing mechanisms,
with special attention to the clinical implications of CaSR-
based therapeutics on Ca2þ and Mg2þ handling.
ROLE OF THE CaSR IN Ca2þ AND Mg2þ HOMEOSTASIS
Parathyroid gland
Maintenance of the plasma ionized Ca2þ and an Mg2þ
concentration within a narrow range (1.12–1.32 and 0.44–
0.59 mmol/l, respectively) relies on the coordinated actions
of the kidney, intestine, and bone under the hormonal and
sensing control by the parathyroid glands (Figure 1).
In response to hypocalcemia, reduced binding of Ca2þ to
CaSR in the parathyroid induces rapid PTH release from
secretory granules, delays PTH degradation, and eventually
results in parathyroid hyperplasia (Figure 2). Increased levels
of circulating PTH restore normal plasma Ca2þ values
through: (i) resorption of Ca2þ from bone; (ii) directly
increasing Ca2þ reabsorption in the distal part of the
nephron via the transient receptor potential vanilloid 5
(TRPV5)18 channel; and (iii) stimulating activation of
vitamin D (1,25-dihydroxyvitamin D3 (1,25(OH)2D3), or
calcitriol) synthesis in the cells of the proximal tubule
of the nephron. 1,25(OH)2D3 promotes absorption of dietary
Ca2þ in the small intestine and release of Ca2þ mineralized
in bones. As negative feedback, 1,25(OH)2D3 represses
the transcription of PTH19 and may have an indirect effect
on PTH release by increasing the expression of CaSR
(Figure 2).20
In a hypercalcemic situation, CaSR inhibits PTH release
and stimulates the secretion of calcitonin by the thyroid
C cells. Calcitonin secretion represents a robust defense
against hypercalcemia via decreased osteoclast-mediated bone
resorption.21
While hormonal regulation governing Ca2þ (re)absorp-
tion and mobilization from tissues has been extensively
investigated, the regulatory mechanisms responsible for the
systemic Mg2þ handling are still largely unknown.
Generally, Mg2þ can modulate PTH secretion in a way
similar to Ca2þ .22–24 Increasing Mg2þ levels inhibits PTH
release25 and reduces agonist-stimulated cAMP accumulation in
parathyroid.26 Furthermore, diverse studies in either hemo- or
peritoneal dialysis patients have reported an inverse relationship
between plasma PTH and dialysate Mg2þ content.27,28 Never-
theless, in different expression systems, Ca2þ has been found
to be a more potent stimulator of PTH secretion than
Mg2þ .23,25,29 However, in vivo, the concentration of Mg2þ in
the local microenvironment within the parathyroid might differ
significantly from its level in the blood.
The differences between the effects of Ca2þ and Mg2þ on
the CaSR-mediated secretory responses might reside in their
ability to bind to the receptor and/or in their involvement in

























Figure 1 | Schematic representation of Ca2þ and Mg2þ
homeostasis. Dashed arrow: paracellular transport; solid arrow:
transcellular transport. CaSR, calcium-sensing receptor; CLDN16,
claudin-16; CLDN19, claudin-19; CNT, connecting tubule; DCT,
distal convoluted tubule; PTH, parathyroid hormone; PT, proximal
tubule; TAL, thick ascending limb of Henle; TRPM6, transient
receptor potential melastatin 6; TRPV4, transient receptor
potential vanilloid 4; TRPV5, transient receptor potential vanilloid























Figure 2 |Key regulators of PTH expression and PTH secretion
in a parathyroid gland cell model. Fluctuations in plasma Ca2þ
and Mg2þ levels modulate PTH release from secretory granules
via CaSR-mediated signaling. In hypocalcemic conditions,
1,25(OH)2D3 can bind its receptor VDR and act as negative
feedback mechanism on PTH and CaSR promoters. When
hyperphosphatemia occurs, FGF23 binds to the Klotho/FGFR1
complex and inhibits the PTH expression and release. More
recently, it has been hypothesized that the NaK-ATPase/Klotho
complex can regulate PTH secretion. CaSR, calcium-sensing
receptor; 1,25(OH)2D3, 1,25-dihydroxyvitamin D3; FGFR1, FGF
receptor 1; FGF23, fibroblast growth factor 23; NaK-ATPase,
Naþ–Kþ ATPase pump; PTH, parathyroid hormone; VDR, vitamin
D receptor.
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publication by Li et al.31 reports for the first time a second-
messenger role for Mg2þ in receptor-induced phospholipase
Cg1 and Ca2þ signaling in lymphoid and non-lymphoid
tissues. Their findings suggest that Ca2þ transport into the
intracellular compartment can be secondary to Mg2þ influx.
Further research should investigate how fluctuations in the
intracellular Mg2þ concentration in the parathyroid glands
influence CaSR signaling, Ca2þ influx, and, ultimately, PTH
secretion.
Kidney
Renal CaSR is an integral component of the homeostatic
mechanisms that locally regulate mineral and water reabsorp-
tion in a PTH-independent manner.32 In the kidney, CaSR is
expressed widely along the nephron and exhibits segment-
specific cellular polarization (Figure 1).
In the proximal tubule of the nephron, CaSR is apical and
its expression is modulated by 1,25(OH)2D3,
20,33 PTH, and
dietary Pi.
34 In this segment, CaSR controls PTH-dependent
Pi excretion and can affect 1,25(OH)2D3 synthesis via the
renal cytochrome P450 enzyme 25-hydroxyvitamin D3-1a-
hydroxylase.35,36 The majority of Ca2þ and Mg2þ reabsorp-
tion occurs in the PT and in the thick ascending limb of
Henle (TAL) via passive paracellular transport mediated by
claudin-16 and claudin-19 (Figure 1).37 Claudin-16 and
claudin-19 proteins form cation-permeable channels, and,
when mutated, are a cause of familial hypomagnesemia with
hypercalciuria and nephrocalcinosis (FHHNC; OMIM
248250).37 Interestingly, CaSR agonists (such as Ca2þ and
Mg2þ ) can induce lysosomal degradation of claudin-16
in vitro. In the kidney, this would lead to Ca2þ and Mg2þ
wasting in the pro-urine.38
In TAL, the apical Naþ–Kþ–2Cl cotransporter NKCC2
and the renal outer medullary potassium channel renal outer
medullary potassium (ROMK) generate a lumen-positive
transepithelial potential difference, which drives cation
reabsorption (largely Ca2þ and Mg2þ , but also Naþ )
through the paracellular route.39 During hypercalcemia,
activation of the basolateral CaSR inhibits ROMK and
NKCC2, resulting in the dissipation of the driving force for
paracellular transport, leading to Naþ , Ca2þ , and Mg2þ
wasting.40 Similarly, pharmacological inhibition of NKCC2 by
furosemide completely abolishes the transepithelial voltage
gradient across the TAL, and therefore drastically inhibits
Ca2þ and Mg2þ reabsorption. Mutations in the genes for
NKCC2, ROMK, CaSR, the chloride channel ClC-kb, and its
accessory protein Barttin are the causative defects for different
variants of the salt-wasting disorder known as Bartter’s
syndrome.41–43 Although all of the Bartter’s syndrome types
are caused by inhibition of transport in the TAL due to a full
or partial dissipation of the electrochemical gradient, there is
a considerable and unexplained variability in the conse-
quences of faulty divalent cation handling.44
In the distal convoluted tubule (DCT), Ca2þ and Mg2þ
reabsorption relies on active transcellular processes. The early
DCT (DCT1) determines the final urinary Mg2þ concentration
by reabsorbing 5–10% of the filtered Mg2þ via the epithelial
transient receptor potential melastatin 6 (TRPM6) (Fig-
ure 1).45,46 Recent studies demonstrated that CaSR activity
reduces cell surface expression of the basolateral Kþ channel
Kir4.1.47 This channel provides Kþ ions to the NaK-ATPase,
which maintains a local negative membrane potential essential
for transcellular Mg2þ reabsorption in DCT1.48,49 Evidence for
a crosstalk between CaSR and Kir4.1 suggests that activating
mutations in the CaSR11 as well as loss of function mutations
in Kir4.1 (refs. 48, 49) might affect renal Naþ reabsorption and
cause Mg2þ wasting through the same mechanism. In the late
DCT (DCT2) and connecting tubules, CaSR is likely to control
the transcellular Ca2þ reabsorption via modulation of apical
Ca2þ entry through TRPV5 and/or basolateral Ca2þ efflux
mediated by the Naþ–Ca2þ exchanger (NCX1) and the Ca2þ -
ATPase (PMCA1B).50,51 During hypocalcemic conditions,
calciotropic hormones, including 1,25(OH)2D3 and PTH,
increase the expression and/or enhance the channel open
probability of TRPV5.52,53 Experiments conducted in TRPV5
knockout (TRPV5/) mice elucidated an intriguing role of
CaSR in the collecting duct. In this segment of the nephron,
increased urinary Ca2þ levels activate the luminal CaSR,
enhancing activity of the Hþ -ATPase proton pump and
downregulating the aquaporin 2 water channel.54 The con-
sequent decrease in urinary pH and polyuria protects the
TRPV5/ mice from the risk of developing renal CaPi
deposits. These adaptive mechanisms in a renal hypercalciuric
mouse model indicate that renal CaSR and other local molec-
ular actors could be novel therapeutic targets in preventing
kidney stones in humans.
In conclusion, in vivo and in vitro studies showed that
CaSR affects many molecular players involved in the paracel-
lular and transcellular reabsorption of Ca2þ and Mg2þ in
the kidney. Moreover, it provides crucial basolateral- and
luminal-sensing mechanisms that integrate and balance water
and divalent mineral losses.
Bone
The majority of body Ca2þ and Mg2þ is stored in the
osseous tissue as hydroxyapatite, whitlockite, and amorphous
CaPi crystals. Under physiological conditions, the mainte-
nance of mineral stores in bone relies on the equilibrium
between bone mineralization by osteoblasts and bone
resorption by osteoclasts, the latter being a process that leads
to mineral release into the extracellular fluids. Expression
studies in bone reported CaSR transcripts in preosteoblasts
and osteoblasts, as well as in osteoclast precursors and mature
osteoclasts.5,55 Fluctuations in extracellular Ca2þ concentra-
tions in vitro control osteoblast and osteoclast cell fate via
pathways involving CaSR activation.5,56 The bone abnormal-
ities observed in global CaSR knockout mice (CaSR/) do
not represent a conclusive evidence for the importance of the
skeletal CaSR in vivo, as the hypercalcemia and hyperpar-
athyroidism in these animals may be responsible for
secondary effects on bone.57,58 Moreover, CaSR knockout is
incomplete because of the gene targeting strategy that leads
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to the expression of a CaSR splice variant able to compensate
for the loss of full-length CaSR in bone and cartilage of these
animals.59 Chang et al.9 finally proved the critical role of the
osteoblast CaSR in bone development, mineralization, and
resorption, by generating a mouse model with an osteoblast-
specific ablation of CaSR. These mice show profound bone
defects that are independent of the calcitropic hormone axis
and exclusively rely on local regulatory events that involve the
skeletal CaSR.9,10
With respect to Ca2þ transport in bone, the TRP channels
TRPV4, TRPV5, and TRPV6 are known to be involved in this
process, as from in vitro studies and characterization of
knockout mouse models.60–62 At the ruffled border membrane
of osteoclasts, the highly Ca2þ -selective channel TRPV5
participates to remove the mineralized bone matrix (Fig-
ure 1),62,63 whereas TRPV4 regulates intracellular Ca2þ
concentrations both in the osteoclast and osteoblast (Figure 1).60
A recent study demonstrated that TRPV6 is also expressed in
the bone mainly at the luminal side of the osteoclast and in
osteoblasts, but it is not crucial for bone mineralization in mice
(Figure 1).61 Up to now, no regulatory mechanism on TRP
channels by CaSR in bone has been described.
Although Mg2þ stores in bone are the best indicator of
total body Mg2þ , the (patho)physiological role of Mg2þ in
mineral mobilization remains unclear. Hypomagnesemia is
generally associated with reduced bone mineral density in both
rats and humans,64 whereas hypermagnesemia is a risk factor
for the development of adynamic bone disease, a condition
characterized by abnormally low bone turnover.65 In indivi-
duals whose renal function is not compromised, insufficient
dietary Mg2þ intake has been linked to osteoporosis66,67 and
the evidence for a loss of a magnesiotropic action of estrogens
in Mg2þ homeostasis could be important in the develop-
ment of postmenopausal osteoporosis.68 Moreover, the use of
proton-pump inhibitor drugs (PPIs) is associated with
hypomagnesemia and increased risk of fractures.69,70
The mineral disturbances in chronic kidney disease (CKD)
cause a spectrum of skeletal abnormalities, including osteitis
fibrosa, osteomalacia, osteopenia, or osteoporosis, and
adynamic bone disease. In studies on CKD patients, the
differences in the management and complexity of mineral
disturbances make it difficult to delineate a comprehensive
overview of Mg2þ :Ca2þ ratio in bone, renal osteodystrophy,
and total body Mg2þ balance. Before initiation of dialysis,
bone biopsies of end-stage renal disease patients with
different degrees of renal osteodystrophy revealed an increase
in the Mg2þ :Ca2þ ratio with no increase in the total bone
Mg2þ compared with healthy subjects.71 Studies conducted
after 2-year dialysis on a 0.65 mmol/l Mg2þ dialysate showed
an increase in bone Mg2þ content.72 The exact effect of
Mg2þ before and after initiation of dialysis on bone mass,
physical composition, and turnover is still unknown. The
study of channels and transporters permitting Mg2þ to
permeate bone cells and their crosstalk with divalent cation-
sensing mechanisms in bone will elucidate the direct actions
of Mg2þ on skeletal integrity.
Intestine
In mammals, CaSR is expressed in both the luminal and
basolateral membrane of epithelial cells along the entire
length of the small and large intestine. Here, the receptor
plays a role in cell growth and differentiation, fluid transport,
and nutrient sensing.73 Ca2þ and Mg2þ absorption in the
intestine consists of both para- and transcellular pathways,
with the paracellular transport being the predominant route
in high dietary Ca2þ and Mg2þ conditions.74
The majority of ingested Ca2þ is absorbed via a para-
cellular route in multiple segments of the small intestine,
whereas active transcellular Ca2þ absorption mainly occurs
in the duodenum via TRPV6. The majority of Mg2þ is
absorbed from the small intestine via a paracellular route and
to a lesser extent from the colon via transcellular transport.75
Colonic absorption of Mg2þ likely involves TRPM6.45
Overall, the local role of intestinal CaSR on the regulation
of divalent cation homeostasis is still largely unknown.
INTERPLAY OF Ca2þ AND Mg2þ METABOLISM
Genetic diseases of the CaSR suggest that Mg2þ and Ca2þ
are both physiologically relevant CaSR agonists in vivo.
Activating mutations in the CaSR result in autosomal
dominant hypocalcemic hypercalciuria (OMIM 146200) that
is associated with asymptomatic hypocalcemia, low plasma
Mg2þ , and PTH levels in the lower-to-normal range.11
Interestingly, some activating mutations present a more
severe phenotype similar to salt wasting syndrome (Gitel-
man’s and Bartter’s syndromes) with hypocalcemia, low PTH
levels, renal Ca2þ wasting, nephrocalcinosis, hypomagnese-
mia, and hypermagnesuria.11 Inactivating mutations of the
CaSR, on the other hand, result in familial benign autosomal
dominant hypocalciuric hypercalcemia (FHH, OMIM
145980), or its recessive form, neonatal severe hyperpar-
athyroidism (OMIM 239200).76 Patients affected with FHH
or neonatal severe hyperparathyroidism exhibit hypercalce-
mia, hypermagnesemia, and normal to high levels of PTH.
Mouse models for autosomal dominant hypocalcemic
hypercalciuria and FHH resemble the human phenotype of
the diseases.14,15
Mg2þ deficiency has been found to alter Ca2þ metabo-
lism significantly in animals as well as in humans.45,46,77 In
particular, secondary hypocalcemia is commonly observed in
patients with hypomagnesemia. Familial hypomagnesemia
with secondary hypocalcemia (OMIM 602014) is an auto-
somal recessive disorder whose underlying cause is one of
several mutations in the epithelial cation channel
TRPM6.45,46 Unfortunately, homozygous deletion of TRPM6
is embryonically lethal in mice, and therefore limiting our
understanding of the effect of Mg2þ homeostatic defects on
Ca2þ metabolism.78 However, heterozygous deletion of
TRPM6 results in a mild hypomagnesemia with normocalce-
mia.78 In these mice, a Mg2þ -enriched diet could not
compensate for low plasma Mg2þ levels. Similarly, enteral
administration of Mg2þ keeps hypomagnesemia with
secondary hypocalcemia patients normocalcemic, but does
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not fully normalize plasma Mg2þ concentrations.79 This
suggests that the causative defect of hypocalcemia resided in
the kidneys, whereas hypomagnesemia was derived from
intestinal malabsorption of Mg2þ . Subsequently, Walder
et al.46 demonstrated that hypomagnesemia in hypomagne-
semia with secondary hypocalcemia patients also involved
renal Mg2þ wasting. In fact, intravenous Mg2þ loading
restored plasma Mg2þ and Ca2þ levels, with affected
individuals having a lower threshold of urine Mg2þ excretion
compared with control individuals. In accordance with other
studies, Mg2þ supplementation increased urinary Ca2þ
excretion.68,80 Bonny and co-workers80 showed that the
increased calciuric response to Mg2þ loading is a PTH-
independent process that probably originates from the
inhibition of TRPV5 by extracellular Mg2þ in the distal
part of the nephron. Whether the binding of Mg2þ to the
renal CaSR is involved in this process is unknown. In
addition, a competitive transport of Mg2þ and Ca2þ via the
common paracellular route in the TAL could explain the
coupling between the urinary Mg2þ and Ca2þ excretion in
response to different extracellular Mg2þ levels.68
In the parathyroid glands, hypomagnesemia is expected
to increase PTH secretion.22–24 Nevertheless, chronic Mg2þ
deficiency can lead to the suppression of PTH release.81–86
Most probably, prolonged hypomagnesemia causes intracel-
lular Mg2þ depletion that in turn is responsible for the
constitutive activation of the CaSR signaling, block of PTH
secretion, and ultimately secondary hypocalcemia due to
decreased reabsorption of Ca2þ by the kidney.30 Thus, the
occurrence of either an acute or a chronic Mg2þ deficiency is
likely on the basis of the discrepancies observed in the ability of
this cation to modulate PTH release in the parathyroid glands.
Another hypothesis is that hypomagnesemia causes
hypocalcemia due to the skeletal resistance to PTH. In vitro
studies revealed that exposure to low extracellular Mg2þ
concentrations causes less Ca2þ release from cultured fetal
rat bone cells.87 Similarly, bones from Mg2þ -depleted
animals released less Ca2þ than control bones when exposed
to PTH.88 Nevertheless, a PTH-independent mode could also
be involved.89
The study of Mg2þ homeostasis in experimental models
of Ca2þ -homeostatic disturbances will enable us to dissect
the inter-regulatory mechanisms and the molecular players
involved in the metabolism of these two cations.62,90,91
PERTURBATIONS IN Ca2þ AND Mg2þ METABOLISM IN
RENAL FAILURE
Disturbances of mineral metabolism, primarily hyperphos-
phatemia, are common during the course of CKD, and are
classically accompanied by secondary hyperparathyroidism,
bone disorders, and ectopic calcifications in soft tissues.
Under physiological conditions, the bone–kidney–parathyroid
axis controls Pi and Ca
2þ homeostasis via a regulatory loop
that includes the fibroblast growth factor 23 (FGF23), Klotho,
1,25(OH)2D3, and PTH. Klotho was first identified as an
aging suppressor.92 It is mainly expressed in the kidney and
parathyroid as single-span transmembrane protein, but is
also secreted in blood and urine upon extracellular shedding.
Secreted and intact Klotho exerts multiple biological actions
in Pi and Ca
2þ metabolism. In the DCTs of the kidney,
Klotho has a stimulatory effect on TRPV5 activity,93 whereas
in the parathyroid glands, it enhances the cell surface
expression of the NaK-ATPase pump to generate the driving
force for PTH secretion (Figure 2).94 Moreover, Klotho works
as co-receptor for the phosphaturic hormone FGF23.95,96
Circulating Pi and 1,25(OH)2D3 positively regulate FGF23
release from bone.97,98 Binding of the secreted FGF23 to the
Klotho/FGFR1 complex suppresses Pi reabsorption and
1,25(OH)2D3 synthesis, in the kidney,
99 whereas it decreases
PTH secretion, in the parathyroid.100 Klotho expression is
induced by 1,25(OH)2D3
101 and repressed by FGF23.102 With
the progression of CKD, Klotho levels decline,103 causing
FGF23 resistance, significant increase in FGF23 and PTH
release, hypovitaminosis D, and hyperphosphatemia. Dele-
tions of Klotho (Klotho/) or FGF23 (FGF23/) in a mouse
model lead to hyperphosphatemia, vascular calcification, and
osteopenia, a phenotype that resembles the mineral and bone
disease observed in CKD.91,92 On the other hand, Hu et al.103
showed that transgenic mice overexpressing Klotho devel-
oped less severe vascular calcifications via a direct inhibition
of Pi uptake by vascular smooth muscle cells (VSMC) in
combination with enhanced phosphaturia and improved
glomerular filtration. The authors confirmed that Klotho
supplementation might have therapeutic potential for CKD,
as previously proposed by Nakatani et al.104,105 The current
therapy for mineral and bone disorder in CKD mainly
includes: use of 1,25(OH)2D3 analogs, use of calcimimetic
agents, control of Pi via dietary restrictions, and use of oral Pi
binders, parathyroidectomy, and adjustment of dialysate
mineral composition.
In addition to Pi and Ca
2þ imbalance, renal failure is the
most common cause of hypermagnesemia. With the progres-
sion of CKD (glomerular filtration rate o30 ml/min),
urinary Mg2þ excretion may be insufficient to balance
intestinal Mg2þ absorption, therefore causing high
plasma Mg2þ levels. Dietary control of Mg2þ intake and
the Mg2þ content of the dialysate are largely responsible for
controlling Mg2þ balance in dialysis patients. The Mg2þ
concentration commonly used in peritoneal dialysis solutions
is 0.25–0.75 mmol/l and 0.75 mmol/l in hemodialysis, and is
directly related to plasma Mg2þ concentrations.27,28 Recent
studies reported that circulating Mg2þ levels inversely
correlate with vascular calcification among end-stage renal
disease patients106 and with carotid intima–media thickness in
hemodialysis patients.107 As cardiovascular disease accounts
for premature death in about 50% of dialysis patients, the
monitoring of plasma Mg2þ together with Ca2þ and Pi is
crucial in CKD patients. In the general population, Mg2þ acts
as a vasodilator and influences blood pressure, in part, by
regulating peripheral vascular resistance and reactivity.108
Mg2þ deficiency is associated with endothelium dysfunction
and atherosclerosis, whereas Mg2þ administration is linked to
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a decrease in blood pressure and significant improvement of
endothelial function and VSMC response.109 In patients
affected by Gitelman’s syndrome, characterized by hypocal-
ciuria and hypomagnesemia, Mg2þ also reduced the recur-
rence of acute ectopic deposition of idiopathic CaPi crystals in
the extracellular fluid.110
Vascular calcification occurs in the vessel walls via a
combination of extracellular and intracellular nanocrystal
deposition, cellular differentiation towards an osteoblast-like
phenotype, and cell apoptosis.111 A recent study in a rat
model of chronic renal failure showed that the calcimimetic
AMG 641 could slow down the progression of vascular
calcification.112 Moreover, in vitro, calcimimetic R-568
inhibited mineral deposition in VSMC via local activation
of CaSR.113,114 CaSR expression in the VSMC decreases, as the
vessels calcify, following the progression of kidney failure.115
One of the TRPC channels is probably responsible for Ca2þ
entry in VSMC after CaSR activation.116 As extracellular
Mg2þ has been shown to negatively regulate calcification in
VSMC through increased activity of the cation channel
TRPM7,117 it would be interesting to investigate whether
Mg2þ entry can modulate CaSR-mediated Ca2þ influx in
these cells.
Another therapeutic option in CKD patients makes use of
vitamin D derivatives. 1,25(OH)2D3 sterols lowers PTH levels
and minimizes hyperphosphatemia by stimulating skeletal
FGF23 secretion. FGF23/ and Klotho/ mice exhibit
atherosclerosis and ectopic calcifications.92,92 Lowering the
plasma Pi levels or genetically reducing 1,25(OH)2D3 rescued
much of the phenotype in Klotho/ mice, suggesting both a
vitamin D-dependent and -independent inhibition of ectopic
calcifications.118 In accordance with observations in uremic
animals, the use of 1,25(OH)2D3 analogs in CKD patients
is associated with a decrease in intima–media thickness
and coronary artery calcification.119 Of note, the use of
1,25(OH)2D3 analogs before the initiation of dialysis and in
more advanced stage of CKD, when vitamin D resistance
occurs, needs to be carefully monitored to prevent hypercal-
cemia, hyperphosphatemia, and metastatic calcifications.
It has been reported that vitamin D increases Mg2þ
absorption in the jejunum.120 Nevertheless, increased plasma
Mg2þ levels due to therapy with vitamin D derivatives might
not be sufficient to reduce PTH release in the parathyroid
gland via CaSR activation and to prevent medial calcification
in arteries.
As renal function deteriorates, the control of Pi relies on
the use of agents that bind ingested Pi in the intestinal lumen
to limit its absorption.121 To this end, a variety of compounds
with different limitations have been used, that is, aluminum
hydroxide, Ca2þ -based compounds, Mg2þ salts, and non-
Ca2þ containing, non-aluminum containing Pi binders. The
use of Mg2þ salts in patients with renal failure before
initiation of dialysis should be monitored to avoid the side
effects of hypermagnesemia, but they can be safely used in
combination with low Mg2þ dialysate. Mg2þ -based Pi
binders may contribute to lower PTH levels by a calcimimetic
effect of Mg2þ on CaSR in the parathyroid glands and at the
same time may improve cardiovascular outcomes via local
CaSR modulation. It seems worthwhile to investigate whether
Ca2þ–Mg2þ combined preparations represent a suitable
compromise between effectiveness, low toxicity, low risk of
hypercalcemia, and beneficial effects on the cardiovascular
system.122 As mineralized vessels and bone are both
composed of mainly hydroxyapatite, whitlockite, and CaPi
crystals, unravelling the differential ion transporters and
sensors involved in vascular calcification and bone formation
is essential for the development of target-specific Ca2þ - or
Mg2þ -based therapies.111
ALTERNATIVE Ca2þ - AND Mg2þ -SENSING MECHANISMS
CaSR/ mice die within the first few weeks of life due to the
severe hypercalcemia and hyperparathyroidism,15 confirming
the central, non-redundant role of the CaSR in mineral ion
metabolism. Nevertheless, the existence of other functional
CaSR variants or alternative Ca2þ -sensing mechanisms
cannot be excluded.59 Positional cloning approaches in
families with FHH provide evidence for the existence of
alternative receptors or mediators of Ca2þ regulation,
mapping at loci other than CaSR.123,124 FHH consists of
three defined types, FHH1, FHH2, and FHH3 (also referred
to as Oklahoma variant, FHHOk), whose chromosomal
locations are 3q21.1, 19p, and 19q13, respectively.123,125,126
FHH1 is caused by mutations in the CaSR gene in more than
65% of patients, but the abnormalities underlying FHH2 and
FHH3 are unknown.127 Genes that reside in the associated
candidate regions might encode for other Ca2þ sensors or
proteins involved in processes upstream or downstream of
CaSR activation.128
The actions of Ca2þ could potentially also be mediated by
one or more of the metabotropic glutamate receptors that
sense Ca2þ (i.e. metabotropic glutamate receptors 1, 3, and
5). Interestingly, the extracellular domain of the G protein–-
coupled receptors CaSR, g-aminobutyric acid B and
metabotropic glutamate receptors show a significant degree
of sequence homology to the bacterial periplasmic nutrient-
binding protein. One of the bacterial periplasmic nutrient-
binding proteins, named PhoQ, acts as extracellular Mg2þ
sensor.129 PhoQ induces production of Mg2þ transport
proteins in response to environmental Mg2þ deprivation in
Salmonella. Although phylogenetics is a constant aid to
Mg2þ research in eukaryotes,130 so far none of the known
eukaryotic proteins responsive to Mg2þ has been associated
with divalent cation-sensing properties.131
CONCLUSIONS
Primary disturbances of the Ca2þ balance often display a
concomitant disturbance of Mg2þ homeostasis and vice
versa. Nevertheless, the cascades of cellular and molecular
events that lead to the combined disturbances of these cations
are mostly unknown. While the hormonal regulation
governing Ca2þ reabsorption and mobilization from tissues
has been largely investigated, a comprehensive regulatory
1162 Kidney International (2012) 82, 1157–1166
rev iew S Ferre` et al.: Sensing mechanisms in Ca2þ and Mg2þ homeostasis
mechanism describing systemic Mg2þ handling is still
missing. So far, the epidermal growth factor132 and estro-
gens68 are the only magnesiotropic hormones known to
directly affect Mg2þ metabolism via stimulation of the
epithelial Mg2þ channel TRPM6.
The CaSR plays a unique role in sensing systemic and local
fluctuations of both Ca2þ and Mg2þ concentrations. In the
parathyroid, the effects of elevated levels of Mg2þ on CaSR
mimic those of Ca2þ , as Mg2þ can similarly modulate PTH
secretion. Moreover, CaSR plays important regulatory roles
in other tissues independent of the calcitropic hormone axis.
For example, mutations in the CaSR cause disturbances in
Ca2þ , Mg2þ , and water reabsorption, mainly due to defects
in renal CaSR signaling. The study of CaSR-mediated events
following Ca2þ and Mg2þ sensing in health and disease
provide insights into the regulation of Ca2þ and Mg2þ
handling.
Currently, calcimimetics that target the CaSR are success-
fully applied to control secondary hyperparathyroidism in
CKD patients by lowering circulating PTH, Pi, and Ca
2þ
levels, which in turn decreases vascular calcifications.
Interestingly, extracellular Mg2þ negatively regulates vascular
calcification and osteogenic differentiation in the presence
of high Pi and high Ca
2þ concentrations. It has been
hypothesized that calcimimetics, as well as Mg2þ , can
activate local cation-sensing mechanisms that protect
from ectopic mineralization processes. This observation
evokes some interesting hypotheses that remain untested:
(i) the existence of alternative CaSR isoforms involved in
local sensing of divalent cations; (ii) the existence of an
unknown Mg2þ sensor; and (iii) a role of intracellular
Mg2þ in the regulation of CaSR-mediated events that lead
to Ca2þ entry.
In conclusion, the central role of the CaSR in the tight
coupling of Ca2þ and Mg2þ metabolism suggests that the
homeostasis of both these divalent cations has to be carefully
monitored during the treatment of mineral disorders.
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